HT
MDGL icon

Headlands Technologies’s Madrigal Pharmaceuticals MDGL Stock Holding History

Headlands Technologies’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-3,953
Closed -$839K – 1438
2024
Q3 		$839K Buy
+3,953
New +$1.01M 0.1% 229
2024
Q2 		– Sell
-61
Closed -$16.3K – 1429
2024
Q1 		$16.3K Sell
61
-1,984
-97% -$467K ﹤0.01% 946
2023
Q4 		$473K Buy
+2,045
New +$358K 0.14% 142

Other funds holding MDGL

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Headlands Technologies's MDGL Position: Q4 2024 in Review

Headlands Technologies sold out of Madrigal Pharmaceuticals (MDGL) in Q4 2024, closing a stake of 3,953 shares — an estimated $839K sold.

Headlands Technologies first reported a position in MDGL in Q4 2023 and held it in 3 quarters. The position peaked at $839K in Q3 2024. 283 funds tracked by Wall St. Rank hold MDGL as of Q4 2024.

  • Headlands Technologies reported no remaining Madrigal Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Headlands Technologies sold 3,953 Madrigal Pharmaceuticals shares in Q4 2024, an estimated $839K.
  • Headlands Technologies first reported a position in Madrigal Pharmaceuticals in Q4 2023 and held it in 3 quarters.
  • Headlands Technologies's Madrigal Pharmaceuticals position peaked at $839K in Q3 2024.
  • 283 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q4 2024.

Based on Headlands Technologies's 13F filing for Q4 2024, filed 12 Feb 2025.